Applied Economics & Statistics | Faculty
Dianne Farina Sisofo
- Ph.D. Biostatistics Medical College of Virginia, Virginia Commonwealth University, Richmond, VA
- B.S. in Statistics/ Minor in Mathematics, Radford University, Radford, VA
- STAT200
- STAT409
- STAT609
- STAT674
Dissertation:“The Development of D-Optimal Designs for Exponential Survival Models”, April 1997
Publications:Trachtman,H., Farina,D.R., “The Relationship Between Calcium and Sodium Intake,
Race and Blood Pressure In Children With Renal Insufficiency: A Report of the
Growth Failure in Children With Renal Diseases(GFRD) Study1.” Journal of the
American Society of Nephrology 1995; Volume6, Number1,126-131.
Staszewski, S., Farina, D. R., “Efavirenz Plus Zidovudine and Lamivudine, Efavirenz
Plus Indinavir, and Indinavir Plus Zidovudine and Laminvudine in the Treatment of
HIV-1 Infection in Adults. “ The New England Journal of Medicine, Dec. 1999,
Volume 341, Number 25.
Posters:
Staszewski, S. “A Phase III, Multicenter, Randomized, Open-Label Study to Compare
the Antiretroviral Activity and Tolerability of EFV+IDV, Versus EFV+ZDV+3TC,
Versus IDV+ZDV+3TC at 24 Weeks [DMP266-006]” The 12th World AIDS
Conference, Geneva, Switzerland, June 1998.
Tashima, K., Staszewski, S., Morales-Ramirez, J., Stryker, R., Johnson, P., Farina, D. R., “A Phase III, Multicenter, Randomized, Open-Label Study to Compare the Antiretroviral Activity and Tolerability of Efavirenz+ZDV+3TC, Versus Indinavir+ZDV+3TC, Versus Efavirenz+Indinavir(Study 006); January 1997-October 1998” 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, Feb. 1999.
Staszewski, S., Morales-Ramirez, J.O., Godofsky, E. W., Stryker, R., Tashima, K., Farina, D.R., “Longer Time-to-Treatment Failure and Durability of Response with Efavirenz+ZDV+3TC: First Analysis of Full 1266 Patient Cohort from Study 006” 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, Sept. 1999.
Moyle, G.J., Nelson, M., Ruiz, N.M., Manion, D.J., Labriola, D. F., Farina, D. R. “Time To Treatment Success: 24 Weeks Is Not Enough in Patients Starting with High Viral Load in DPC-006” , Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept. 2000.
Rachlis, Becker, Gill, DeJesus, Pierone, Kirkland, Kooshian, Farina, Ruiz, Bessen, Villano, “Successful Substitution of Protease Inhibitors with SUSTIVATM (Efavirenz) in Patients with Undetectable Plasma HIV-1 RNA Levels: Results of a Prospective, Randomized, Multicenter, Open-Label Study (DMP-049)”, , Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, Sept. 2000.
Abstracts:
Farina,D.R., Carter, W.H. “Development of D and Q Optimal Designs for Survival
Analysis.” Twelfth Annual Daniel T. Watts Student Research Symposium,
Oct. 1995.
Espinel-Ingroff,A., Farina,D.R. “Second NCCLS Evaluation of Antifungal
Susceptibility Testing of Filamentous Fungi.” Abstracts of the 35th ICAAC,
Sept. 1995.
